 Drug Therapy, Combination
"Drug Therapy, Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapy with two or more separate preparations given for a combined effect.
| Descriptor ID |
D004359
|
| MeSH Number(s) |
E02.319.310
|
| Concept/Terms |
Drug Therapy, Combination- Drug Therapy, Combination
- Combination Chemotherapy
- Drug Polytherapy
- Drug Polytherapies
- Polytherapies, Drug
- Polytherapy, Drug
- Therapy, Combination Drug
- Chemotherapy, Combination
- Chemotherapies, Combination
- Combination Chemotherapies
- Combination Drug Therapy
- Combination Drug Therapies
- Drug Therapies, Combination
- Therapies, Combination Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Therapy, Combination".
Below are MeSH descriptors whose meaning is more specific than "Drug Therapy, Combination".
This graph shows the total number of publications written about "Drug Therapy, Combination" by people in this website by year, and whether "Drug Therapy, Combination" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 5 | 5 | | 1995 | 0 | 6 | 6 | | 1996 | 0 | 5 | 5 | | 1997 | 0 | 6 | 6 | | 1998 | 0 | 12 | 12 | | 1999 | 0 | 10 | 10 | | 2000 | 0 | 13 | 13 | | 2001 | 1 | 10 | 11 | | 2002 | 1 | 7 | 8 | | 2003 | 0 | 14 | 14 | | 2004 | 0 | 28 | 28 | | 2005 | 1 | 24 | 25 | | 2006 | 0 | 25 | 25 | | 2007 | 0 | 21 | 21 | | 2008 | 0 | 20 | 20 | | 2009 | 0 | 17 | 17 | | 2010 | 0 | 24 | 24 | | 2011 | 0 | 36 | 36 | | 2012 | 0 | 36 | 36 | | 2013 | 2 | 24 | 26 | | 2014 | 0 | 32 | 32 | | 2015 | 0 | 54 | 54 | | 2016 | 1 | 36 | 37 | | 2017 | 2 | 49 | 51 | | 2018 | 1 | 38 | 39 | | 2019 | 0 | 40 | 40 | | 2020 | 1 | 38 | 39 | | 2021 | 0 | 30 | 30 | | 2022 | 0 | 11 | 11 | | 2023 | 0 | 11 | 11 | | 2024 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Therapy, Combination" by people in Profiles.
-
Utzschneider KM, Younes N, Butera NM, Balasubramanyam A, Bergenstal RM, Barzilay J, DeSouza C, DeFronzo RA, Elasy T, Krakoff J, Kahn SE, Rasouli N, Valencia WM, Sivitz WI. Impact of Insulin Sensitivity and ?-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy. Diabetes Care. 2024 Apr 01; 47(4):571-579.
-
Baker JF, ODell JR, England BR, Giles JT, Newcomb JA, George MD, Thiele G, Moreland L, Bridges SL, Curtis JR, Mikuls TR. Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis. Ann Rheum Dis. 2024 Mar 12; 83(4):429-436.
-
Karamanis A, Bleacher H, DeSanto K. Effectiveness of ICS/LABA Compared With SABA as Relief Medications for Asthma. Am Fam Physician. 2023 11; 108(5):515-516.
-
Rymer J, Anand SS, Sebastian Debus E, Haskell LP, Hess CN, Jones WS, Muehlhofer E, Berkowitz SD, Bauersachs RM, Bonaca MP, Patel MR. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation. 2023 12 12; 148(24):1919-1928.
-
Faridi KF, Strom JB, Kundi H, Butala NM, Curtis JP, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky EA, Yeh RW. Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. J Am Heart Assoc. 2023 07 18; 12(14):e029588.
-
Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Cayl? JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 06 16; 76(12):2090-2097.
-
Demarest S, Jeste S, Agarwal N, Arkilo D, Asgharnejad M, Hsiao S, Thibert R. Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE). Epilepsy Behav. 2023 05; 142:109173.
-
Weissler EH, Stebbins A, Wruck L, Mu?oz D, Gupta K, Girotra S, Whittle J, Benziger CP, Polonsky TS, Bradley SM, Hammill BG, Merritt JG, Zemon DN, Hernandez AF, Jones WS. Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study. Vasc Med. 2023 04; 28(2):122-130.
-
Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, Cayla JA, Chen M, Feng PJ, Moro RN, Holland DP, Martinson N, Millet JP, Miro JM, Belknap R. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 06; 129:107173.
-
Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|